Skip to main content
Clinical Trials/NCT03927820
NCT03927820
Active, not recruiting
Not Applicable

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

Vanderbilt University Medical Center1 site in 1 country914 target enrollmentStarted: September 9, 2019Last updated:
ConditionsCOPDAsthma

Overview

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
914
Locations
1
Primary Endpoint
Time to either hospital readmission or ER visit

Overview

Brief Summary

The goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or Emergency Department (ED) visit.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patient admitted to Vanderbilt University Medical Center (VUMC) (excluding surgery services)
  • on a long acting inhaler or prescribed a long acting inhaler during admission.

Exclusion Criteria

  • Diagnosis of cystic fibrosis
  • Diagnosis of graft versus host disease (GVHD)
  • no medication insurance
  • discharge to any post-acute care facility or inpatient hospice
  • death during hospitalization

Outcomes

Primary Outcomes

Time to either hospital readmission or ER visit

Time Frame: 6 months

Combined time (days) to either hospital readmission or emergency department visit after hospitalization (all outcomes measured at 6 months post-discharge with a 3 month interim analysis)

Secondary Outcomes

  • frequency of prescribed inhaler at discharge(6 months)
  • frequency of hospital readmissions(6 months)
  • frequency of short course prescription of oral steroid(6 months)
  • Frequency of ED visit(6 months)
  • time to 1st ED visit (days)(6 months)
  • time to 1st readmission (days)(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Tate Davis

Clinical Pharmacist

Vanderbilt University Medical Center

Study Sites (1)

Loading locations...

Similar Trials